GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (STU:YP2A) » Definitions » Dividends Received

BioLine Rx (STU:YP2A) Dividends Received


View and export this data going back to 2014. Start your Free Trial

What is BioLine Rx Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.


BioLine Rx (STU:YP2A) Business Description

Traded in Other Exchanges
Address
2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.